<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209416</url>
  </required_header>
  <id_info>
    <org_study_id>M-2010-0157</org_study_id>
    <nct_id>NCT01209416</nct_id>
  </id_info>
  <brief_title>The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin</brief_title>
  <official_title>The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the non-growth-hormone-dependent metabolic effects of the hormone&#xD;
      Ghrelin in growth hormone deficient subjects by examining the insulin tolerance as well as&#xD;
      signal proteins in fat and muscle biopsies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ghrelin is a relatively 'new' hormone that is produced in the stomach and to a lesser extend&#xD;
      in the hypothalamus of the brain. The actions of ghrelin are diverse and includes stimulation&#xD;
      of the appetite center of the brain and the release of growth hormone. We have for the first&#xD;
      time shown that ghrelin also stimulates the metabolism of fatty acids and induces insulin&#xD;
      resistance in skeletal muscle. These effects have we confirmed in growth hormone deficient&#xD;
      subjects on a stabile substitution treatment with growth hormone and hydrocortisone. With&#xD;
      these subjects we can investigate the effects of ghrelin that are independent of growth&#xD;
      hormone. The present study is a continuation of these findings, as we wish to investigate&#xD;
      whether the insulin resistance effect of ghrelin is dependent of the concomitant metabolism&#xD;
      of fatty acids. This is possible by administration of the niacin acid antagonist Acipimox,&#xD;
      that blocks the fatty acid metabolism reversibly. We have applied this experimental principle&#xD;
      in other settings with success.&#xD;
&#xD;
      Knowledge of the effects of ghrelin in general can in shot-sight as well as in long-sight&#xD;
      have great importance for the understanding of growth disorders from overweight and type 2&#xD;
      diabetes to malnutrition and eating disorders.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of ghrelin during basal and hyperinsulinemic conditions</measure>
    <time_frame>5 hours investigation day</time_frame>
    <description>Growth hormone deficient patient investigated with ghrelin infusion and pharmacological antilipolysis (Acipimox) in a randomized cross-over study with 4 study days. During each visit signal proteins in muscle and fat biopsies are investigated with PCR, wester blot and activity assays for ghrelin, growth hormone and insulin. Further is glucose metabolism investigated in basal conditions and during hyperinsulinemic euglycemic clamp.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of ghrelin during basal and hyperinsulinemic conditions</measure>
    <time_frame>5 hours investigation day</time_frame>
    <description>Effects of ghrelin on heart rate variability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of ghrelin during basal and hyperinsulinemic conditions</measure>
    <time_frame>5 hours investigation day</time_frame>
    <description>Effects of ghrelin on thirst, fluid intake, urine production and natriuresis</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Metabolism</condition>
  <condition>Insulin Resistance</condition>
  <condition>Hypopituitarism</condition>
  <arm_group>
    <arm_group_label>Ghrelin / Acipimox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ghrelin infusion and tablet acipimox</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ghrelin / placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ghrelin infusion and placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / Acipimox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>saline infusion and tablet Acipimox</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline infusion and placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acipimox</intervention_name>
    <description>Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day</description>
    <arm_group_label>Ghrelin / Acipimox</arm_group_label>
    <arm_group_label>Placebo / Acipimox</arm_group_label>
    <other_name>Tablet Olbetam 250 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ghrelin</intervention_name>
    <description>Ghrelin infusion 4.2 ng/kg/min throughout the investigation day</description>
    <arm_group_label>Ghrelin / Acipimox</arm_group_label>
    <arm_group_label>Ghrelin / placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablets or saline infusion</description>
    <arm_group_label>Ghrelin / placebo</arm_group_label>
    <arm_group_label>Placebo / Acipimox</arm_group_label>
    <arm_group_label>Placebo / placebo</arm_group_label>
    <other_name>Placebo tablets</other_name>
    <other_name>Saline infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  males with hypopituitarism in regard to growth hormone and ACTH in stabile treatment&#xD;
             regime&#xD;
&#xD;
          -  age 18-65&#xD;
&#xD;
          -  BMI 20-35&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  abuse of alcohol&#xD;
&#xD;
          -  malign disease&#xD;
&#xD;
          -  medication other than that expected for hypopituitarism&#xD;
&#xD;
          -  known disease other than hypopituitarism&#xD;
&#xD;
          -  participation in isotope investigations the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Otto L JÃ¸rgensen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Aarhus</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>https://www.nature.com/articles/srep42706</url>
    <description>Original publication on the results from the study</description>
  </link>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ghrelin</keyword>
  <keyword>metabolism</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypopituitarism</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

